UB Paderborn / Katalog / Suche / in CDI

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2018-10, Vol.23 (10), p.1199-1209

2018

Link zum Volltext

Verfügbarkeit prüfen

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Cancer research (Chicago, Ill.), 2011-09, Vol.71 (18), p.6019-6029

2011

Link zum Volltext

Verfügbarkeit prüfen

Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial

Investigational new drugs, 2017-12, Vol.35 (6), p.813-819

2017

Link zum Volltext

Verfügbarkeit prüfen

Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy

Journal for immunotherapy of cancer, 2023-01, Vol.11 (1), p.e005924

2023

Link zum Volltext

Verfügbarkeit prüfen

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

Journal for immunotherapy of cancer, 2022-06, Vol.10 (6), p.e004688

2022

Link zum Volltext

Verfügbarkeit prüfen

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade

Frontiers in oncology, 2022-08, Vol.12, p.945798-945798

2022

Link zum Volltext

Verfügbarkeit prüfen

Molecular Testing for Treatment of Metastatic Non‐Small Cell Lung Cancer: How to Implement Evidence‐Based Recommendations

The oncologist (Dayton, Ohio), 2015-10, Vol.20 (10), p.1175-1181

2015

Link zum Volltext

Verfügbarkeit prüfen

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations

JTO clinical and research reports, 2024-06, Vol.5 (6), p.100686, Article 100686

2024

Link zum Volltext

Verfügbarkeit prüfen

Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases

Rheumatic & musculoskeletal diseases open, 2023-10, Vol.9 (4), p.e003471

2023

Link zum Volltext

Verfügbarkeit prüfen

A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer

Cancer treatment and research communications, 2019, Vol.20, p.100150-100150, Article 100150

2019

Link zum Volltext

Verfügbarkeit prüfen

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

The lancet oncology, 2015-03, Vol.16 (3), p.257-265

2015

Link zum Volltext

Verfügbarkeit prüfen

Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?

Clinical advances in hematology & oncology, 2024-06, Vol.22 (5), p.217

2024

Link zum Volltext

Verfügbarkeit prüfen

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

European journal of cancer (1990), 2019-02, Vol.108, p.120-128

2019

Link zum Volltext

Verfügbarkeit prüfen

Survival of Asian females with advanced lung cancer in the era of tyrosine kinase inhibitor therapy

Clinical lung cancer, 2017-01, Vol.18 (1), p.e35-e40

2017

Link zum Volltext

Verfügbarkeit prüfen

TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Future oncology (London, England), 2023-07, Vol.19 (21), p.1461-1472

2023

Link zum Volltext

Verfügbarkeit prüfen

Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy

Journal of neurosurgery, 2022-01, Vol.136 (1), p.56-66

2022

Link zum Volltext

Verfügbarkeit prüfen

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

Oncology (Williston Park, N.Y.), 2016-07, Vol.30 (7), p.601-612

2016

Link zum Volltext

Verfügbarkeit prüfen

Influence of Extent of Lymph Node Evaluation on Survival for Pathologically Lymph Node Negative Non-Small Cell Lung Cancer

American journal of clinical oncology, 2018-08, Vol.41 (8), p.820-825

2018

Link zum Volltext

Verfügbarkeit prüfen

Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer

Clinical lung cancer, 2022-11, Vol.23 (7), p.620-629

2022

Link zum Volltext

Verfügbarkeit prüfen

The time for low-dose computed tomography screening is now: a medical oncologist perspective

Oncology (Williston Park, N.Y.), 2014-11, Vol.28 (11), p.964-966

2014

Link zum Volltext

Verfügbarkeit prüfen

The time for low-dose computed tomography screening is now: a medical oncologist perspective.(Commentary on the Grannis 'Perspective': Benjamin P. Levy, Daniel J. Becker)

Oncology (Williston Park, N.Y.), 2014-11, Vol.28 (11), p.956

2014

Link zum Volltext

Verfügbarkeit prüfen

Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer

Oncology (Williston Park, N.Y.), 2014-06, Vol.28 (6), p.526, 528, 530, 534-534

2014

Link zum Volltext

Verfügbarkeit prüfen

Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target?

Oncology (Williston Park, N.Y.), 2010-09, Vol.24 (10), p.888-900

2010

Link zum Volltext

Verfügbarkeit prüfen

Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs

Journal of oncology practice, 2017-07, Vol.13 (7), p.e653

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non‐Small Cell Lung Cancer

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial

Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy

Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade

Molecular Testing for Treatment of Metastatic Non‐Small Cell Lung Cancer: How to Implement Evidence‐Based Recommendations

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations

Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases

A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Antibody-drug conjugates in advanced lung cancer: Is this a new frontier?

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

Survival of Asian females with advanced lung cancer in the era of tyrosine kinase inhibitor therapy

TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

Influence of Extent of Lymph Node Evaluation on Survival for Pathologically Lymph Node Negative Non-Small Cell Lung Cancer

Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer

Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

The time for low-dose computed tomography screening is now: a medical oncologist perspective

The time for low-dose computed tomography screening is now: a medical oncologist perspective.(Commentary on the Grannis 'Perspective': Benjamin P. Levy, Daniel J. Becker)

Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer

Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target?

Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs

Suchergebnisse filtern